Management Dr. Stephan Fischer CEO Dr. Fischer spent 26 years in R&D at Boehringer-Mannheim/Roche Pharma Research where he focused on the discovery and development of biological based therapeutics. Stephan was a member of the team that developed erythropoietin (NeoRecormon®) and was the scientific and global project leader of the team that developed the thrombolytic reteplase (Retavase®, Rapilysin®) from discovery to launch. Stephan was a member of the global regulatory strategy committee for Biologics and the global task force for biosimilars. As Senior Vice President, Stephan led the Biologics research organization and developed the global strategy for Roche Biologicals with a focus on innovation and new technologies. Stephan received his PhD in Microbiology and conducted his post-doc at the European Molecular Biology Labs. Dr. Hans-Willi Krell VP Operations For over 26 years at Boehringer Mannheim / Roche, Dr. Krell was responsible for the development of high through put assays and screening of new diagnostic and biotechnological enzymes, natural compounds and low molecular weight compounds. More recently, Hans has focused on the discovery and characterization of novel therapeutic antibodies, employing innovative biochemical and cellular based screens. In addition, Hans has been actively involved in global project management. Hans (co-) authored more than 40 patent applications and 60 publications. Hans holds a PhD from Freiburg University in biochemistry. Corporate Overview Management Advisory Board About Us Technology Partnering News Contact Careers HomeImpressumSite Map

Partners In December 2015, Sanofi and MAB Discovery signed a collaboration agreement for the development of antibodies against selected targets. In May 2014, Synthon and MAB Discovery entered into a multi-target antibody discovery agreement. In March 2014, MAB Discovery signed a multi-target deal with Genmab A/S for the development of therapeutic antibody products. In March 2013, MAB Discovery entered into a collaboration with BioNTech of Mainz, Germany to discover monoclonal antibodies to a number of targets. In July 2012, MAB Discovery entered into an agreement with an undisclosed US biotech company to develop monoclonal antibodies to a number of targets. In June 2012, MAB Discovery entered into an agreement with Boehringer Ingelheim for the generation of monoclonal antibodies. Business Model Partners About Us Technology Partnering News Contact Careers HomeImpressumSite Map